Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Human Urinary Kallidinogenase on Inflammatory Factors in Acute Ischemic Stroke (KIF-AIS)
NCT06696703Recruiting
- Sponsor
- The First Affiliated Hospital of Harbin Medical University
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of human urinary kallidinogenase + Shuxuening injection in ischemic stroke (2 arms), sponsored by The First Affiliated Hospital of Harbin Medical University. Primary endpoints: Favorable Stroke Outcome (mRS) at 90 days and Changes in serum inflammatory markers at 90 days. Started Jan 2024; status: recruiting.
02
Drugs
human urinary kallidinogenase + Shuxuening injection
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06696703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06696703.